Overexpression of MN1 Confers Resistance to Chemotherapy, Accelerates Leukemia Onset, and Suppresses p53 and Bim Induction

por Pardee, Timothy S.
Publicado 2012

The Efficacy of the Ribonucleotide Reductase Inhibitor Didox in Preclinical Models of AML

por Cook, Guerry J., Caudell, David L., Elford, Howard L., Pardee, Timothy S.
Publicado 2014

The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C()

por Alexander, Peter M., Kucera, Gregory L., Pladna, Kristin M., Pardee, Timothy S.
Publicado 2020

The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells

por Pardee, Timothy S., Stadelman, Kristin, Jennings-Gee, Jamie, Caudell, David L., Gmeiner, William H.
Publicado 2014

The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia

por Alexander, Peter M., Caudell, David L., Kucera, Gregory L., Pladna, Kristin M., Pardee, Timothy S.
Publicado 2017

Pyruvate Dehydrogenase Inhibition Leads to Decreased Glycolysis, Increased Reliance on Gluconeogenesis and Alternative Sources of Acetyl-CoA in Acute Myeloid Leukemia

por Anderson, Rebecca, Pladna, Kristin M., Schramm, Nathaniel J., Wheeler, Frances B., Kridel, Steven, Pardee, Timothy S.
Publicado 2023

The prognostic value of standardized phase angle in adults with acute leukemia: A prospective study

por Yates, Samuel J., Lyerly, Susan, Manuel, Megan, Tooze, Janet A., Klepin, Heidi D., Powell, Bayard L., Dralle, Sarah, Uprety, Alok, Pardee, Timothy S.
Publicado 2020

A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma

por Lycan, Thomas W., Pardee, Timothy S., Petty, William J., Bonomi, Marcelo, Alistar, Angela, Lamar, Zanetta S., Isom, Scott, Chan, Michael D., Miller, Antonius A., Ruiz, Jimmy
Publicado 2016

A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia

por Seegars, Mary Beth, Woods, Ryan, Ellis, Leslie R., Bhave, Rupali Roy, Howard, Dianna S., Manuel, Megan, Dralle, Sarah, Lyerly, Susan, Powell, Bayard L., Pardee, Timothy S.
Publicado 2021

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia

por Anderson, Rebecca, Miller, Lance D., Isom, Scott, Chou, Jeff W., Pladna, Kristin M., Schramm, Nathaniel J., Ellis, Leslie R., Howard, Dianna S., Bhave, Rupali R., Manuel, Megan, Dralle, Sarah, Lyerly, Susan, Powell, Bayard L., Pardee, Timothy S.
Publicado 2022

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

por Heuser, Michael, Palmisiano, Neil, Mantzaris, Ioannis, Mims, Alice, DiNardo, Courtney, Silverman, Lewis R., Wang, Eunice S., Fiedler, Walter, Baldus, Claudia, Schwind, Sebastian, Pardee, Timothy, Perl, Alexander E., Cai, Charles, Kaulfuss, Stefan, Lagkadinou, Eleni, Rentzsch, Christine, Wagner, Markus, Wilkinson, Gary, Wu, Bingyan, Jeffers, Michael, Genvresse, Isabelle, Krämer, Alwin
Publicado 2020

A phase 1 study of first-in-class agent CPI-613 in combination with FOLFIRINOX for metastatic pancreatic cancer

por Alistar, Angela, Morris, Bonny B., Desnoyer, Rodwige, Klepin, Heidi D., Hosseinzadeh, Keyanoosh, Clark, Clancy, Cameron, Amy, Leyendecker, John, D’Agostino, Ralph, Topaloglu, Umit, Boteju, Lakmal W., Boteju, Asela R., Shorr, Rob, Zachar, Zuzana, Bingham, Paul M., Ahmed, Tamjeed, Crane, Sandrine, Shah, Riddhishkumar, Migliano, John J., Pardee, Timothy S., Miller, Lance, Hawkins, Gregory, Jin, Guangxu, Zhang, Wei, Pasche, Boris
Publicado 2017